vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and Reborn Coffee, Inc. (REBN). Click either name above to swap in a different company.

FATE THERAPEUTICS INC is the larger business by last-quarter revenue ($1.4M vs $1.4M, roughly 1.0× Reborn Coffee, Inc.). On growth, Reborn Coffee, Inc. posted the faster year-over-year revenue change (7.8% vs -26.4%). Over the past eight quarters, Reborn Coffee, Inc.'s revenue compounded faster (0.1% CAGR vs -15.7%).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

Reborn Coffee, Inc. is a specialty coffee roaster and retailer that offers premium single-origin and blended roasted coffee beans, handcrafted espresso drinks, baked snacks and related merchandise. It operates brick-and-mortar cafe locations primarily across the United States, alongside direct-to-consumer online sales and wholesale distribution to foodservice partners, with a core focus on ethically sourced, high-quality coffee products.

FATE vs REBN — Head-to-Head

Bigger by revenue
FATE
FATE
1.0× larger
FATE
$1.4M
$1.4M
REBN
Growing faster (revenue YoY)
REBN
REBN
+34.2% gap
REBN
7.8%
-26.4%
FATE
Faster 2-yr revenue CAGR
REBN
REBN
Annualised
REBN
0.1%
-15.7%
FATE

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FATE
FATE
REBN
REBN
Revenue
$1.4M
$1.4M
Net Profit
$-3.4M
Gross Margin
Operating Margin
-224.7%
Net Margin
-254.3%
Revenue YoY
-26.4%
7.8%
Net Profit YoY
37.9%
-379.3%
EPS (diluted)
$-0.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
REBN
REBN
Q4 25
$1.4M
Q3 25
$1.7M
$1.4M
Q2 25
$1.9M
$1.8M
Q1 25
$1.6M
$1.7M
Q4 24
$1.9M
$1.8M
Q3 24
$3.1M
$1.3M
Q2 24
$6.8M
$1.4M
Q1 24
$1.9M
$1.5M
Net Profit
FATE
FATE
REBN
REBN
Q4 25
Q3 25
$-32.3M
$-3.4M
Q2 25
$-34.1M
$-5.3M
Q1 25
$-37.6M
$-2.2M
Q4 24
$-1.8M
Q3 24
$-47.7M
$-719.7K
Q2 24
$-38.4M
$-1.3M
Q1 24
$-48.0M
$-990.5K
Gross Margin
FATE
FATE
REBN
REBN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
98.7%
Operating Margin
FATE
FATE
REBN
REBN
Q4 25
Q3 25
-1995.1%
-224.7%
Q2 25
-1938.5%
-240.2%
Q1 25
-2534.1%
-100.2%
Q4 24
-95.2%
Q3 24
-1703.9%
-57.6%
Q2 24
-665.7%
-97.4%
Q1 24
-2652.9%
-56.9%
Net Margin
FATE
FATE
REBN
REBN
Q4 25
Q3 25
-1852.4%
-254.3%
Q2 25
-1786.6%
-291.0%
Q1 25
-2309.5%
-129.4%
Q4 24
-100.0%
Q3 24
-1551.0%
-57.2%
Q2 24
-567.4%
-95.9%
Q1 24
-2493.7%
-65.3%
EPS (diluted)
FATE
FATE
REBN
REBN
Q4 25
Q3 25
$-0.27
$-0.68
Q2 25
$-0.29
$-1.15
Q1 25
$-0.32
$-0.47
Q4 24
$-0.28
Q3 24
$-0.40
$-0.30
Q2 24
$-0.33
$-0.48
Q1 24
$-0.47
$-0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
REBN
REBN
Cash + ST InvestmentsLiquidity on hand
$203.7M
$44.0K
Total DebtLower is stronger
$500.0K
Stockholders' EquityBook value
$207.2M
$-3.4M
Total Assets
$318.9M
$6.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
REBN
REBN
Q4 25
$203.7M
Q3 25
$215.4M
$44.0K
Q2 25
$222.8M
$77.9K
Q1 25
$240.4M
$777.1K
Q4 24
$279.1M
$158.2K
Q3 24
$296.9M
$105.9K
Q2 24
$304.9M
$617.1K
Q1 24
$121.3M
$70.3K
Total Debt
FATE
FATE
REBN
REBN
Q4 25
Q3 25
$500.0K
Q2 25
$500.0K
Q1 25
$500.0K
Q4 24
$500.0K
Q3 24
$500.0K
Q2 24
$500.0K
Q1 24
$500.0K
Stockholders' Equity
FATE
FATE
REBN
REBN
Q4 25
$207.2M
Q3 25
$234.1M
$-3.4M
Q2 25
$261.4M
$-1.9M
Q1 25
$288.4M
$415.6K
Q4 24
$318.7M
$2.6M
Q3 24
$362.3M
$2.7M
Q2 24
$397.0M
$2.5M
Q1 24
$426.1M
$2.6M
Total Assets
FATE
FATE
REBN
REBN
Q4 25
$318.9M
Q3 25
$343.7M
$6.2M
Q2 25
$371.6M
$6.4M
Q1 25
$398.7M
$8.1M
Q4 24
$440.7M
$7.8M
Q3 24
$495.0M
$9.6M
Q2 24
$528.8M
$10.5M
Q1 24
$569.9M
$10.9M
Debt / Equity
FATE
FATE
REBN
REBN
Q4 25
Q3 25
Q2 25
Q1 25
1.20×
Q4 24
0.19×
Q3 24
0.19×
Q2 24
0.20×
Q1 24
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
REBN
REBN
Operating Cash FlowLast quarter
$-106.1M
$-1.6M
Free Cash FlowOCF − Capex
$-112.0M
FCF MarginFCF / Revenue
-8183.9%
Capex IntensityCapex / Revenue
434.8%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-199.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
REBN
REBN
Q4 25
$-106.1M
Q3 25
$-24.4M
$-1.6M
Q2 25
$-24.6M
$-3.6M
Q1 25
$-33.8M
$464.6K
Q4 24
$-122.9M
$-132.6K
Q3 24
$-29.4M
$-424.0K
Q2 24
$-32.3M
$-961.8K
Q1 24
$-33.4M
$-1.9M
Free Cash Flow
FATE
FATE
REBN
REBN
Q4 25
$-112.0M
Q3 25
$-26.6M
Q2 25
$-25.9M
Q1 25
$-35.0M
Q4 24
$-123.6M
$-600.9K
Q3 24
$-29.9M
$-424.0K
Q2 24
$-32.4M
$-1.3M
Q1 24
$-33.4M
$-2.9M
FCF Margin
FATE
FATE
REBN
REBN
Q4 25
-8183.9%
Q3 25
-1526.5%
Q2 25
-1360.7%
Q1 25
-2148.9%
Q4 24
-6645.4%
-33.8%
Q3 24
-973.1%
-33.7%
Q2 24
-477.8%
-95.3%
Q1 24
-1736.9%
-192.4%
Capex Intensity
FATE
FATE
REBN
REBN
Q4 25
434.8%
Q3 25
126.5%
0.0%
Q2 25
71.4%
Q1 25
73.4%
Q4 24
39.2%
26.3%
Q3 24
16.1%
0.0%
Q2 24
0.8%
25.2%
Q1 24
4.5%
65.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FATE
FATE

Segment breakdown not available.

REBN
REBN

Stores$1.1M83%
Other$229.9K17%

Related Comparisons